• Lack of focus in Indian markets is visible: Market share down to 1.4%
  • USA: 139 ANDAs approved
  • F3 facility for General Injectable in Formulations was audited by the FDA and received five observations post-inspection of the USFDA, the same were procedural in nature.
    • Still have not received the EIR; & waiting for the USFDA appearance.
  • Cumulatively invested 822 Crores towards Aleor, our joint venture to develop Dermatology products for the international markets, which also filed 4 ANDAs. Aleor has filed 4 ANDAs and intends on filing 10 ANDAs per annum and commercializing 25-30 products over the next two years.

More here: